SG10201710013RA - Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof - Google Patents
Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereofInfo
- Publication number
- SG10201710013RA SG10201710013RA SG10201710013RA SG10201710013RA SG10201710013RA SG 10201710013R A SG10201710013R A SG 10201710013RA SG 10201710013R A SG10201710013R A SG 10201710013RA SG 10201710013R A SG10201710013R A SG 10201710013RA SG 10201710013R A SG10201710013R A SG 10201710013RA
- Authority
- SG
- Singapore
- Prior art keywords
- pai
- antibodies
- plasminogen activator
- activator inhibitor
- inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361865451P | 2013-08-13 | 2013-08-13 | |
EP14305757 | 2014-05-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201710013RA true SG10201710013RA (en) | 2018-01-30 |
Family
ID=56194112
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201710013RA SG10201710013RA (en) | 2013-08-13 | 2014-08-13 | Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof |
Country Status (17)
Country | Link |
---|---|
US (4) | US9845363B2 (en) |
JP (4) | JP6696899B2 (en) |
KR (1) | KR20160035077A (en) |
CN (2) | CN105705520B (en) |
BR (1) | BR112016002753A2 (en) |
CL (1) | CL2016000324A1 (en) |
CR (2) | CR20190319A (en) |
DO (1) | DOP2016000042A (en) |
EA (1) | EA033403B1 (en) |
ES (1) | ES2770507T3 (en) |
HK (1) | HK1221725A1 (en) |
MX (2) | MX2016001851A (en) |
PE (1) | PE20160244A1 (en) |
PH (1) | PH12016500239A1 (en) |
SG (1) | SG10201710013RA (en) |
TN (1) | TN2016000048A1 (en) |
UA (1) | UA118267C2 (en) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20160035077A (en) * | 2013-08-13 | 2016-03-30 | 사노피 | Antibodies to plasminogen activator inhibitor-1(pai-1) and uses thereof |
CA3008691A1 (en) | 2015-12-18 | 2017-06-22 | Talengen International Limited | Method for preventing or treating diabetic retinopathy |
CA3008186A1 (en) | 2015-12-18 | 2017-06-22 | Talengen International Limited | Novel method for preventing and treating angiocardiopathy |
TWI653981B (en) | 2015-12-18 | 2019-03-21 | 深圳瑞健生命科學硏究院有限公司 | Use of plasminogen for the preparation of a medicament for preventing or treating a condition associated with diabetic nerve injury |
DK3395354T3 (en) | 2015-12-18 | 2024-06-03 | Talengen Int Ltd | Plasminogen for use in the treatment of diabetic nephropathy |
CN108210899A (en) * | 2016-12-15 | 2018-06-29 | 深圳瑞健生命科学研究院有限公司 | Prevent and treat drug of histoorgan fibrosis and application thereof |
CN110191718A (en) * | 2016-12-15 | 2019-08-30 | 泰伦基国际有限公司 | A method of preventing and treating histoorgan fibrosis |
WO2018108161A1 (en) | 2016-12-15 | 2018-06-21 | 深圳瑞健生命科学研究院有限公司 | Method and drug for preventing and treating obesity |
TWI644682B (en) | 2016-12-15 | 2018-12-21 | 深圳瑞健生命科學硏究院有限公司 | Application of plasminogen in preparing medicine for promoting islet cell damage repair |
CN108210895A (en) * | 2016-12-15 | 2018-06-29 | 深圳瑞健生命科学研究院有限公司 | Drug of prevention of arterial atherosis and its complication and application thereof |
CN110167583A (en) | 2016-12-15 | 2019-08-23 | 泰伦基国际有限公司 | A method for the treatment of coronary atherosclerosis and its complication |
WO2018107700A1 (en) * | 2016-12-15 | 2018-06-21 | 深圳瑞健生命科学研究院有限公司 | Method for preventing and treating pathological renal tissue injury |
CA3067890A1 (en) | 2017-06-19 | 2018-12-27 | Talengen International Limited | Method for regulating and controling glp-1/glp-1r and drug |
TW201904990A (en) * | 2017-06-23 | 2019-02-01 | 美商波麥堤克生物治療股份有限公司 | Plasminogen treatment for conditions associated with PAI-1 overexpression |
MA47691A (en) | 2017-08-03 | 2020-01-08 | Alector Llc | ANTI-CD33 ANTIBODIES AND PROCESSES FOR USE |
US20220340665A1 (en) | 2019-09-30 | 2022-10-27 | Renascience Inc. | Inhibitor against expression of immune checkpoint molecule |
IL293195A (en) * | 2019-12-05 | 2022-07-01 | Seagen Inc | Anti-avb6 antibodies and antibody-drug conjugates |
US20230081922A1 (en) * | 2020-02-11 | 2023-03-16 | Talengen International Limited | Method and drug for treating viral pneumonia |
CN111072780B (en) * | 2020-03-24 | 2020-06-23 | 深圳汉盛汇融再生医学科技有限公司 | Leukemia stem cell inhibitor and application thereof in treating chronic granulocytic leukemia |
CN114605550B (en) * | 2020-12-08 | 2023-09-22 | 东莞市朋志生物科技有限公司 | Antibodies against CA19-9, uses thereof and kit for detecting CA19-9 |
CN114686442B (en) * | 2020-12-31 | 2023-11-07 | 广州万孚生物技术股份有限公司 | Hybridoma cell strain and application thereof |
CN114686441B (en) * | 2020-12-31 | 2023-11-03 | 广州万孚生物技术股份有限公司 | Hybridoma cell strain capable of secreting tPAI-C monoclonal antibody and application thereof |
Family Cites Families (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
DK319685A (en) * | 1985-07-12 | 1987-01-13 | Fonden Til Fremme Af Eksperime | MONOCLONAL ANTIBODIES, PROCEDURES FOR PRODUCING ANTIBODIES, HYBRIDOMA CELLS PRODUCING ANTIBODIES, AND USING ANTIBODIES |
US5422245A (en) * | 1985-07-12 | 1995-06-06 | Fonden Til Fremme Af Eksperimental Cancerforskning | Plasminogen activator inhibitor monoclonal antibodies, hybridomas, monoclonal antibody production and use of the antibodies for assay of the inhibitors |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
JP3101690B2 (en) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | Modifications of or for denatured antibodies |
JP2750732B2 (en) * | 1988-04-04 | 1998-05-13 | 帝人株式会社 | Immunoassay method for human plasminogen activator inhibitor 1-human tissue plasminogen activator complex |
ATE120454T1 (en) | 1988-06-14 | 1995-04-15 | Cetus Oncology Corp | COUPLING AGENT AND STERICALLY HINDERED CONJUGATES THEREOF BOUND WITH DISULFIDE. |
US6780613B1 (en) | 1988-10-28 | 2004-08-24 | Genentech, Inc. | Growth hormone variants |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
IE63847B1 (en) | 1989-05-05 | 1995-06-14 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
US5460785A (en) | 1989-08-09 | 1995-10-24 | Rhomed Incorporated | Direct labeling of antibodies and other protein with metal ions |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
ATE158615T1 (en) | 1990-03-20 | 1997-10-15 | Univ Columbia | CHIMERIC ANTIBODIES WITH RECEPTOR-BINDING LIGANDS IN PLACE OF THEIR CONSTANT REGION |
JPH09506761A (en) | 1990-11-09 | 1997-07-08 | ステファン ディー.ギリーズ | Immune complex of cytokines |
DE69233482T2 (en) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Method for reducing the immunogenicity of antibody variable domains |
ES2136092T3 (en) | 1991-09-23 | 1999-11-16 | Medical Res Council | PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES. |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
DK85193D0 (en) * | 1993-07-16 | 1993-07-16 | Cancerforskningsfondet Af 1989 | SUPPRESSION OF INHIBITORS |
GB9422383D0 (en) | 1994-11-05 | 1995-01-04 | Wellcome Found | Antibodies |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
JPH1014592A (en) * | 1996-07-04 | 1998-01-20 | Tanabe Seiyaku Co Ltd | Monoclonal antibody to rat pai-1 |
JP2001506967A (en) | 1996-08-02 | 2001-05-29 | ブリストル―マイヤーズ・スクイブ・カンパニー | Methods for suppressing immunoglobulin-induced toxicity as a result of the use of immunoglobulins in therapy and in vivo diagnosis |
WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
GB2339430A (en) | 1997-05-21 | 2000-01-26 | Biovation Ltd | Method for the production of non-immunogenic proteins |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
ATE375365T1 (en) | 1998-04-02 | 2007-10-15 | Genentech Inc | ANTIBODIES VARIANTS AND FRAGMENTS THEREOF |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
EP1105427A2 (en) | 1998-08-17 | 2001-06-13 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
EP1006183A1 (en) | 1998-12-03 | 2000-06-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Recombinant soluble Fc receptors |
CN1202128C (en) | 1998-12-08 | 2005-05-18 | 拜奥威神有限公司 | Method for reducing immunogenicity of proteins |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
PL220113B1 (en) | 1999-01-15 | 2015-08-31 | Genentech Inc | Variant of parent polypeptide comprising the Fc region, polypeptide comprising a variant of the Fc region with altered binding affinity of Fc gamma receptor (FcγR), a polypeptide comprising the variant of Fc region with altered binding affinity of neonatal Fc receptor (FcRn), a composition, isolated nucleic acid, vector, host cell, method for preparing the polypeptide variant, the use of the polypeptide variant and method for preparing a the Fc region variant |
US20020102208A1 (en) | 1999-03-01 | 2002-08-01 | Paul Chinn | Radiolabeling kit and binding assay |
MY133346A (en) | 1999-03-01 | 2007-11-30 | Biogen Inc | Kit for radiolabeling ligands with yttrium-90 |
WO2001051085A1 (en) * | 2000-01-14 | 2001-07-19 | Tanox, Inc. | Use of antagonists of plasminogen activator inhibitor-1 (pai-1) for the treatment of asthma and chronic obstructive pulmonary disease |
WO2002034776A2 (en) | 2000-10-26 | 2002-05-02 | K.U.Leuven Research And Development | Epitopes of pai-1 |
GB0029407D0 (en) | 2000-12-01 | 2001-01-17 | Affitech As | Product |
ES2727425T3 (en) | 2000-12-12 | 2019-10-16 | Medimmune Llc | Molecules with prolonged half-lives, compositions and uses thereof |
CA2476761A1 (en) * | 2002-02-19 | 2003-08-28 | Vanderbilt University | Therapeutic methods employing pai-1 inhibitors and transgenic non-human animal for screening candidate pai-1 inhibitors |
US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
KR20040088572A (en) | 2002-03-01 | 2004-10-16 | 이뮤노메딕스, 인코오포레이티드 | Bispecific antibody point mutations for enhancing rate of clearance |
US20040043026A1 (en) | 2002-05-13 | 2004-03-04 | Tai-Lan Tuan | Treatment and prevention of abnormal scar formation in keloids and other cutaneous or internal wounds or lesions |
US7538195B2 (en) * | 2002-06-14 | 2009-05-26 | Immunogen Inc. | Anti-IGF-I receptor antibody |
CA2495251C (en) | 2002-08-14 | 2018-03-06 | Macrogenics, Inc. | Fc.gamma.riib-specific antibodies and methods of use thereof |
CA2832136C (en) | 2002-09-27 | 2015-11-17 | Xencor | Optimized fc variants and methods for their generation |
EP1562972B1 (en) | 2002-10-15 | 2010-09-08 | Facet Biotech Corporation | ALTERATION OF FcRn BINDING AFFINITIES OR SERUM HALF-LIVES OF ANTIBODIES BY MUTAGENESIS |
CA2512729C (en) | 2003-01-09 | 2014-09-16 | Macrogenics, Inc. | Identification and engineering of antibodies with variant fc regions and methods of using same |
CN1871259A (en) | 2003-08-22 | 2006-11-29 | 比奥根艾迪克Ma公司 | Improved antibodies having altered effector function and methods for making the same |
GB0324368D0 (en) | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
WO2005047327A2 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
EP1697520A2 (en) | 2003-12-22 | 2006-09-06 | Xencor, Inc. | Fc polypeptides with novel fc ligand binding sites |
WO2005070963A1 (en) | 2004-01-12 | 2005-08-04 | Applied Molecular Evolution, Inc | Fc region variants |
AU2005227326B2 (en) | 2004-03-24 | 2009-12-03 | Xencor, Inc. | Immunoglobulin variants outside the Fc region |
WO2005123780A2 (en) | 2004-04-09 | 2005-12-29 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
WO2006085967A2 (en) | 2004-07-09 | 2006-08-17 | Xencor, Inc. | OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS |
EP1919950A1 (en) | 2004-07-15 | 2008-05-14 | Xencor, Inc. | Optimized fc variants |
WO2006047350A2 (en) | 2004-10-21 | 2006-05-04 | Xencor, Inc. | IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION |
US20090202524A1 (en) | 2007-10-31 | 2009-08-13 | Alcon Research, Ltd. | Pai-1 expression and activity inhibitors for the treatment of ocular disorders |
KR101599704B1 (en) | 2007-08-29 | 2016-03-07 | 사노피 | Humanized anti-CXCR5 antibodies, derivatives thereof and their uses |
US7981415B2 (en) | 2007-09-07 | 2011-07-19 | Cisthera, Inc. | Humanized PAI-1 antibodies |
EP2198055A4 (en) | 2007-09-07 | 2012-04-18 | Cisthera Inc | Humanized pai-1 antibodies |
US8410251B2 (en) * | 2008-06-20 | 2013-04-02 | National University Corporation Okayama University | Antibody against calcified globule and use of the same |
US20100254979A1 (en) | 2009-03-06 | 2010-10-07 | Cisthera, Incorporated | Humanized PAI-1 Antibodies and Uses Thereof |
WO2011139974A2 (en) * | 2010-05-03 | 2011-11-10 | Abbott Laboratories | Anti-pai-1 antibodies and methods of use thereof |
KR20160035077A (en) * | 2013-08-13 | 2016-03-30 | 사노피 | Antibodies to plasminogen activator inhibitor-1(pai-1) and uses thereof |
-
2014
- 2014-08-13 KR KR1020167005652A patent/KR20160035077A/en not_active Application Discontinuation
- 2014-08-13 CN CN201480055157.2A patent/CN105705520B/en active Active
- 2014-08-13 BR BR112016002753A patent/BR112016002753A2/en not_active Application Discontinuation
- 2014-08-13 ES ES14761451T patent/ES2770507T3/en active Active
- 2014-08-13 CN CN202010898460.6A patent/CN112142845A/en active Pending
- 2014-08-13 TN TN2016000048A patent/TN2016000048A1/en unknown
- 2014-08-13 UA UAA201602278A patent/UA118267C2/en unknown
- 2014-08-13 CR CR20190319A patent/CR20190319A/en unknown
- 2014-08-13 MX MX2016001851A patent/MX2016001851A/en unknown
- 2014-08-13 JP JP2016534815A patent/JP6696899B2/en active Active
- 2014-08-13 US US14/911,429 patent/US9845363B2/en active Active
- 2014-08-13 PE PE2016000243A patent/PE20160244A1/en unknown
- 2014-08-13 SG SG10201710013RA patent/SG10201710013RA/en unknown
- 2014-08-13 EA EA201690377A patent/EA033403B1/en not_active IP Right Cessation
-
2016
- 2016-02-03 DO DO2016000042A patent/DOP2016000042A/en unknown
- 2016-02-03 PH PH12016500239A patent/PH12016500239A1/en unknown
- 2016-02-10 MX MX2019008803A patent/MX2019008803A/en unknown
- 2016-02-10 CL CL2016000324A patent/CL2016000324A1/en unknown
- 2016-03-07 CR CR20160117A patent/CR20160117A/en unknown
- 2016-08-17 HK HK16109838.9A patent/HK1221725A1/en unknown
-
2017
- 2017-11-10 US US15/809,935 patent/US20180155444A1/en not_active Abandoned
-
2019
- 2019-08-06 US US16/533,048 patent/US20190359729A1/en not_active Abandoned
-
2020
- 2020-04-23 JP JP2020076578A patent/JP6907380B2/en active Active
-
2021
- 2021-06-29 JP JP2021107196A patent/JP7223069B2/en active Active
-
2022
- 2022-06-17 US US17/843,777 patent/US20230015181A1/en active Pending
-
2023
- 2023-02-02 JP JP2023014335A patent/JP2023055852A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20230015181A1 (en) | 2023-01-19 |
BR112016002753A2 (en) | 2017-11-21 |
JP2020125333A (en) | 2020-08-20 |
JP6696899B2 (en) | 2020-05-20 |
PH12016500239A1 (en) | 2016-05-16 |
JP2016529255A (en) | 2016-09-23 |
US20190359729A1 (en) | 2019-11-28 |
EA201690377A1 (en) | 2016-06-30 |
JP2023055852A (en) | 2023-04-18 |
JP7223069B2 (en) | 2023-02-15 |
JP2021155440A (en) | 2021-10-07 |
ES2770507T3 (en) | 2020-07-01 |
HK1221725A1 (en) | 2017-06-09 |
MX2019008803A (en) | 2019-09-16 |
CR20160117A (en) | 2016-05-20 |
US20180155444A1 (en) | 2018-06-07 |
JP6907380B2 (en) | 2021-07-21 |
US20160200831A1 (en) | 2016-07-14 |
CL2016000324A1 (en) | 2016-10-21 |
CR20190319A (en) | 2019-08-29 |
MX2016001851A (en) | 2016-05-16 |
US9845363B2 (en) | 2017-12-19 |
TN2016000048A1 (en) | 2017-07-05 |
PE20160244A1 (en) | 2016-05-10 |
UA118267C2 (en) | 2018-12-26 |
DOP2016000042A (en) | 2016-04-04 |
CN112142845A (en) | 2020-12-29 |
KR20160035077A (en) | 2016-03-30 |
EA033403B1 (en) | 2019-10-31 |
CN105705520B (en) | 2020-09-25 |
CN105705520A (en) | 2016-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1221725A1 (en) | Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof -1(pai-1) | |
IL244018A0 (en) | Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof | |
IL261743B (en) | Anti-il-33 antibodies and uses thereof | |
IL261547B (en) | Anti-hepcidin antibodies and uses thereof | |
IL245040B (en) | Anti-pdgfr-beta antibodies and uses thereof | |
HK1217107A1 (en) | Alpha synuclein antibodies and uses thereof | |
IL243974A0 (en) | Anti-prlr antibodies and uses thereof | |
ZA201508896B (en) | Anti-c10orf54 antibodies and uses thereof | |
ZA201603308B (en) | Novel anti-claudin antibodies and methods of use | |
IL245946A0 (en) | Novel anti-dpep3 antibodies and methods of use | |
SG11201509116VA (en) | Anti-tweakr antibodies and uses thereof | |
IL245663A0 (en) | Anti-siglec-8 antibodies and methods of use thereof | |
HK1223112A1 (en) | Anti-tnf-alpha/cxcl10 double-targeting antibody and use thereof -tnf-/cxcl10 | |
IL244590A0 (en) | Anti-epcam antibodies and methods of use | |
HK1223950A1 (en) | Monoclonal olfml-3 antibodies and uses thereof olfml-3 |